Skip to main content

Table 3 Cell cycle distribution of U266 MM cell line treated with SSTR ligands and 7C11

From: Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells

Treatment G0-G1 (%) S (%) G2-M (%) Sub-G1 (%)
Control 56,6 ± 3,0 25,1 ± 2,3 12,4 ± 1,1 2,5 ± 0,3
Sst 10 μM 57,4 ± 2,0 26,3 ± 0,8 9,6 ± 1,8 3,3 ± 0,2
Css 10 μM 60,8 ± 2,4 20,7 ± 2,4 11,2 ± 0,1 3,7 ± 0,8
Sst 10 μM/Css 10 μM 57,3 ± 2,2 26,2 ± 0,9 10,0 ± 2,5 2,9 ± 0,4
7C11 39,9 ± 1,5* 26,8 ± 1,1 9,9 ± 1,0 16,0 ± 0,9*
7C11/Sst 10 μM 40,3 ± 1,8* 27,2 ± 0,4 8,6 ± 1,1 14,0 ± 0,7*
7C11/Sst 10 μM/Css 10 μM 38,3 ± 3,3* 27,3 ± 1,0 8,9 ± 0,8 12,0 ± 1,1*
Oct 10 μM 55,2 ± 4,6 25,1 ± 3,5 13,6 ± 1,5 3,0 ± 0,5
Oct 10 μM/Css 10 μM 55,6 ± 4,7 24,9 ± 3,6 12,6 ± 1,6 4,0 ± 0,8
7C11/Oct 10 μM 43,1 ± 0,5* 27,2 ± 1,7 12,2 ± 1,5 13,6 ± 1,9*
7C11/Oct 10 μM/Css 10 μM 41,9 ± 0,8* 26,4 ± 2,6 8,1 ± 0,4 18,2 ± 4,6*
  1. U266 cells were pretreated or not (control) with Sst, Oct, Css or the agonistic Fas antibody 7C11 (7C11) for 72 h. Cells were stained with PI, analyzed by flow cytometry and each fraction of the cell cycle was determined using Wincycle®. Data are mean ± S.E.M. of 3 independent experiments. *, ANOVA followed by Bonferroni-Dunn (p < 0.05), statistically significant differences compared to control cells.